1
|
Luzuriaga-Neira N, Ennis K, Moens MA, Leon J, Reyes N, Luzuriaga-Neira A, Rau JR, Rojas-VeraPinto R. The Andean Ibis ( Theristicus branickii) in South America: potential distribution, presence in protected areas and anthropic threats. PeerJ 2023; 11:e16533. [PMID: 38099301 PMCID: PMC10720468 DOI: 10.7717/peerj.16533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2023] [Accepted: 11/07/2023] [Indexed: 12/17/2023] Open
Abstract
The avifauna of South America is one of the most widely studied groups of vertebrates. However, certain species, such as the Andean Ibis (Theristicus branickii), have received limited attention regarding their ecological patterns, biology, current distribution, and environmental requirements. This study analyzed observation data from the Global Biodiversity Information Facility (GBIF) on the Andean Ibis in four countries to identify and understand critical variables that determine the species' presence, assess the proportion of its habitat within protected areas and identify possible threats to the species. Additionally, this study considered environmental and ecological variables to model ecological niches using the maximum entropy approach in MaxEnt to map the suitable habitat of the species. The findings revealed the extent of suitable Andean Ibis habitats in Ecuador, Peru, Bolivia and Chile. The variables that most determined the presence of the species were: altitude (36.57%), distance to lakes (23.29%) and ecological isothermality (13.34%). The distribution area of the Andean Ibis totaled 300,095.00 km2, spanning both sides of the Andean mountains range. Human activities have left a significant impact on the Andean Ibis habitat, with 48% of this area impacted by the human footprint and only 10% of the territory falling within protected areas designated by the respective countries. The results of this study show that the Andean Ibis presents characteristics of a specialist species due to its adaptation to the climate conditions of the plateau and highlands, including low temperatures, herbaceous vegetation and the presence of water bodies. The species is distributed in disconnected Andean landscape areas, whose functionality could be compromised by increased human activities. Complementary studies will be necessary to understand the ecological role and effectiveness of protected areas for conserving the species.
Collapse
Affiliation(s)
- Nivia Luzuriaga-Neira
- Unidad de Estudios de la Vida Silvestre-Facultad de Medicina Veterinaria, Universidad Central del Ecuador, Quito, Pichincha, Ecuador
| | - Keenan Ennis
- School of Natural Resources, Knoxville College, Knoxville, TN, United States of America
| | | | - Jose Leon
- Fundación de Conservación Jocotoco, Quito, Pichincha, Ecuador
| | - Nathaly Reyes
- Unidad de Estudios de la Vida Silvestre-Facultad de Medicina Veterinaria, Universidad Central del Ecuador, Quito, Pichincha, Ecuador
| | - Agusto Luzuriaga-Neira
- Department of Ornithology, American Museum of Natural History, New York, NY, United States of America
- Biology Department, University of Nevada - Reno, Reno, NV, United States of America
| | - Jaime R. Rau
- Laboratorio de Ecología, Departamento de Ciencias Biológicas & Biodiversidad, Universidad de los Lagos, Osorno, Chile
| | | |
Collapse
|
2
|
Orós M, Perejón D, Serna MC, Siscart J, Leon J, Ortega M, Salinas-Roca B. Prevalence and risk factors of gestational diabetes in the health region of Lleida: a retrospective observational cohort study. J Endocrinol Invest 2023; 46:2639-2646. [PMID: 37330946 PMCID: PMC10632204 DOI: 10.1007/s40618-023-02120-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/13/2023] [Accepted: 05/20/2023] [Indexed: 06/20/2023]
Abstract
BACKGROUND Diabetes is a very common metabolic condition during pregnancy. The number of cases increases with age and obesity. The prevalence of pre-gestational diabetes and gestational diabetes (GD) differs between different ethnic groups. OBJECTIVE The aim of the study was to analyse the prevalence of pre-gestational diabetes and GD in the health region of Lleida. We also studied the GD risk factors during pregnancy according to the country of origin of the pregnant woman. METHODS We performed a retrospective observational cohort study among pregnant women between 2012 and 2018 in the health region of Lleida. A multivariate model was performed with the different variables analysed by calculating the regression coefficient and its 95% confidence interval (CI). RESULTS In our sample of 17,177 pregnant women, we observed a prevalence of pre-gestational diabetes and GD of 8.2% and 6.5%, respectively. We found a relationship of gestational diabetes with different factors: age, with 6.8% in 30-34 year-old women and 11.3% in women over 35 (OR 1.78 and 3.29, respectively); overweight, with 8.29% (OR 1.89); and obesity, with 12.9% (OR 3.15). Finally, women from Asia and the Middle East and the Maghreb had a higher risk of diabetes, with 12.2% (OR 2.1) and 9.91% (OR 1.3), respectively, and Sub-Saharan women had a lower risk of it 6.07% (OR 0.71). CONCLUSIONS GD has different risk factors, such as age, overweight, and obesity. Non-related conditions include hypothyroidism, arterial hypertension, and dyslipidaemia. Finally, pregnant women from the Maghreb, and Asia and the Middle East, are at higher risk of developing diabetes during pregnancy; meanwhile, Sub-Saharan origin is protector factor.
Collapse
Affiliation(s)
- M Orós
- Institut d'Investigació en Atenció Primària IDIAP Jordi Gol, Institut Català de la Salut, Lleida, Spain
- Centre de Salut Eixample, Institut Català de la Salut, Lleida, Spain
- Departament de Medicina Familiar, Universitat de Lleida, Lleida, Spain
| | - D Perejón
- Institut d'Investigació en Atenció Primària IDIAP Jordi Gol, Institut Català de la Salut, Lleida, Spain
- Centre de Salut Eixample, Institut Català de la Salut, Lleida, Spain
- Departament de Medicina Familiar, Universitat de Lleida, Lleida, Spain
| | - M C Serna
- Institut d'Investigació en Atenció Primària IDIAP Jordi Gol, Institut Català de la Salut, Lleida, Spain
- Centre de Salut Eixample, Institut Català de la Salut, Lleida, Spain
- Departament de Medicina Familiar, Universitat de Lleida, Lleida, Spain
| | - J Siscart
- Institut d'Investigació en Atenció Primària IDIAP Jordi Gol, Institut Català de la Salut, Lleida, Spain
- Centre de Salut Eixample, Institut Català de la Salut, Lleida, Spain
- Departament de Medicina Familiar, Universitat de Lleida, Lleida, Spain
| | - J Leon
- Departament d'Endocrinologia i Nutrició, Hospital Universitari Arnau de Vilanova, Lleida, Spain
- Grup d'investigació en Immunologia i Metabolisme (GRIM), Institut de Recerca Biomèdica, Lleida, Spain
| | - M Ortega
- Institut d'Investigació en Atenció Primària IDIAP Jordi Gol, Institut Català de la Salut, Lleida, Spain
- Departament de Medicina Familiar, Universitat de Lleida, Lleida, Spain
- Grup de Recerca Terapèutica en Atenció Primària (GRETAPS), Institut Català de la Salut, Lleida, Spain
| | - B Salinas-Roca
- Department of Nursing and Physiotherapy, University of Lleida, Montserrat Roig 2, 25198, Lleida, Spain.
- Global Research On Wellbeing (GRoW) Research Group, Blanquerna School of Health Science, Ramon Llull University, Padilla, 326-332, 08025, Barcelona, Spain.
| |
Collapse
|
3
|
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA. Addendum. 3. Prevention or Delay of Type 2 Diabetes and Associated Comorbidities: Standards of Care in Diabetes-2023. Diabetes Care 2023;46(Suppl. 1):S41-S48. Diabetes Care 2023; 46:1716-1717. [PMID: 37356031 PMCID: PMC10552402 DOI: 10.2337/dc23-ad08a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/12/2013] [Accepted: 09/28/2013] [Indexed: 06/27/2023]
|
4
|
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Cusi K, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA. Erratum. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2023. Diabetes Care 2023;46(Suppl. 1):S49-S67. Diabetes Care 2023; 46:1722. [PMID: 37356013 PMCID: PMC10465983 DOI: 10.2337/dc23-er09a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/27/2023]
|
5
|
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Cusi K, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA. Addendum. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2023. Diabetes Care 2023;46(Suppl. 1):S49-S67. Diabetes Care 2023; 46:1718-1720. [PMID: 37356015 PMCID: PMC10552195 DOI: 10.2337/dc23-ad09] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/27/2023]
|
6
|
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA. Addendum. 2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes-2023. Diabetes Care 2023;46(Suppl. 1):S19-S40. Diabetes Care 2023; 46:1715. [PMID: 37356047 PMCID: PMC10552401 DOI: 10.2337/dc23-ad08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/27/2023]
|
7
|
Ortega-Legaspi J, Molina M, Leon J, Cunningham A, Guerraty M, Peyster E, Julien H, McLean R, Goldberg L, Bravo P. Coronary Flow Reserve is an Independent Predictor of Major Adverse Cardiovascular Events in Long Term Heart Transplantation Survivors. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.171] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
8
|
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA. Erratum. 2. Classification and diagnosis of diabetes: Standards of Care in Diabetes-2023. Diabetes Care 2023;46(Suppl. 1):S19-S40. Diabetes Care 2023; 46:1106. [PMID: 36724041 PMCID: PMC10154657 DOI: 10.2337/dc23-er05] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
In Table 2.3 of the article cited above, the hypertension risk factor was incorrectly defined as "≥140/90 mmHg or on therapy for hypertension"; this has been corrected to "≥130/80 or on therapy for hypertension." More information on updated hypertension guideline recommendations can be found in Section 10 of Standards of Care in Diabetes-2023, "Cardiovascular Disease and Risk Management" (https://doi.org/10.2337/dc23-S010). The online version of the article (https://doi.org/10.2337/dc23-S002) has been updated to correct the error.
Collapse
|
9
|
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Das SR, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Kosiborod M, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA. Erratum. 10. Cardiovascular disease and risk management: Standards of Care in Diabetes-2023. Diabetes Care 2023;46(Suppl. 1):S158-S190. Diabetes Care 2023; 46:898. [PMID: 36700978 PMCID: PMC10090895 DOI: 10.2337/dc23-er04] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Fig. 10.2 of the article cited above provides recommendations for the treatment of confirmed hypertension in people with diabetes. Due to a composition error, the initial blood pressure range for the left side of the algorithm was given as ≥140/90 and <160/100 mmHg; the correct initial blood pressure range is ≥130/80 and <160/100 mmHg. The online version of the article (https://doi.org/10.2337/dc23-S010) has been updated to correct the error.
Collapse
|
10
|
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Cusi K, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA, on behalf of the American Diabetes Association. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2023. Diabetes Care 2023; 46:S49-S67. [PMID: 36507651 PMCID: PMC9810472 DOI: 10.2337/dc23-s004] [Citation(s) in RCA: 57] [Impact Index Per Article: 57.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Collapse
|
11
|
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA. 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes-2023. Diabetes Care 2023; 46:S128-S139. [PMID: 36507637 PMCID: PMC9810466 DOI: 10.2337/dc23-s008] [Citation(s) in RCA: 59] [Impact Index Per Article: 59.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Collapse
|
12
|
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Cusi K, Das SR, Gibbons CH, Giurini JM, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Kosiborod M, Leon J, Lyons SK, Murdock L, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Sun JK, Woodward CC, Young-Hyman D, Gabbay RA. Introduction and Methodology: Standards of Care in Diabetes-2023. Diabetes Care 2023; 46:S1-S4. [PMID: 36507647 PMCID: PMC9810461 DOI: 10.2337/dc23-sint] [Citation(s) in RCA: 51] [Impact Index Per Article: 51.0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
13
|
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Young-Hyman D, Gabbay RA, on behalf of the American Diabetes Association. 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes-2023. Diabetes Care 2023; 46:S68-S96. [PMID: 36507648 PMCID: PMC9810478 DOI: 10.2337/dc23-s005] [Citation(s) in RCA: 104] [Impact Index Per Article: 104.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Collapse
|
14
|
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Gibbons CH, Giurini JM, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Sun JK, Gabbay RA, on behalf of the American Diabetes Association. 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2023. Diabetes Care 2023; 46:S203-S215. [PMID: 36507636 PMCID: PMC9810462 DOI: 10.2337/dc23-s012] [Citation(s) in RCA: 50] [Impact Index Per Article: 50.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Collapse
|
15
|
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA, on behalf of the American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023. Diabetes Care 2023; 46:S140-S157. [PMID: 36507650 PMCID: PMC9810476 DOI: 10.2337/dc23-s009] [Citation(s) in RCA: 301] [Impact Index Per Article: 301.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Collapse
|
16
|
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA, on behalf of the American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes-2023. Diabetes Care 2023; 46:S19-S40. [PMID: 36507649 PMCID: PMC9810477 DOI: 10.2337/dc23-s002] [Citation(s) in RCA: 498] [Impact Index Per Article: 498.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Collapse
|
17
|
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA. 7. Diabetes Technology: Standards of Care in Diabetes-2023. Diabetes Care 2023; 46:S111-S127. [PMID: 36507635 PMCID: PMC9810474 DOI: 10.2337/dc23-s007] [Citation(s) in RCA: 110] [Impact Index Per Article: 110.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Collapse
|
18
|
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA, on behalf of the American Diabetes Association. 14. Children and Adolescents: Standards of Care in Diabetes-2023. Diabetes Care 2023; 46:S230-S253. [PMID: 36507640 PMCID: PMC9810473 DOI: 10.2337/dc23-s014] [Citation(s) in RCA: 57] [Impact Index Per Article: 57.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Collapse
|
19
|
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Cusi K, Das SR, Gibbons CH, Giurini JM, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Kosiborod M, Leon J, Lyons SK, Murdock L, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Sun JK, Woodward CC, Young-Hyman D, Gabbay RA. Summary of Revisions: Standards of Care in Diabetes-2023. Diabetes Care 2023; 46:S5-S9. [PMID: 36507641 PMCID: PMC9810459 DOI: 10.2337/dc23-srev] [Citation(s) in RCA: 43] [Impact Index Per Article: 43.0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
20
|
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA, on behalf of the American Diabetes Association. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2023. Diabetes Care 2023; 46:S191-S202. [PMID: 36507634 PMCID: PMC9810467 DOI: 10.2337/dc23-s011] [Citation(s) in RCA: 84] [Impact Index Per Article: 84.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Collapse
|
21
|
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA, on behalf of the American Diabetes Association. 3. Prevention or Delay of Type 2 Diabetes and Associated Comorbidities: Standards of Care in Diabetes-2023. Diabetes Care 2023; 46:S41-S48. [PMID: 36507633 PMCID: PMC9810464 DOI: 10.2337/dc23-s003] [Citation(s) in RCA: 42] [Impact Index Per Article: 42.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Collapse
|
22
|
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA. 6. Glycemic Targets: Standards of Care in Diabetes-2023. Diabetes Care 2023; 46:S97-S110. [PMID: 36507646 PMCID: PMC9810469 DOI: 10.2337/dc23-s006] [Citation(s) in RCA: 193] [Impact Index Per Article: 193.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Collapse
|
23
|
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Das SR, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Kosiborod M, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA, on behalf of the American Diabetes Association. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2023. Diabetes Care 2023; 46:S158-S190. [PMID: 36507632 PMCID: PMC9810475 DOI: 10.2337/dc23-s010] [Citation(s) in RCA: 142] [Impact Index Per Article: 142.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Collapse
|
24
|
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Murdock L, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Woodward CC, Gabbay RA, on behalf of the American Diabetes Association. 17. Diabetes Advocacy: Standards of Care in Diabetes-2023. Diabetes Care 2023; 46:S279-S280. [PMID: 36507643 PMCID: PMC9810458 DOI: 10.2337/dc23-s017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Collapse
|
25
|
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Jeffrie Seley J, Stanton RC, Gabbay RA, on behalf of the American Diabetes Association. 13. Older Adults: Standards of Care in Diabetes-2023. Diabetes Care 2023; 46:S216-S229. [PMID: 36507638 PMCID: PMC9810468 DOI: 10.2337/dc23-s013] [Citation(s) in RCA: 57] [Impact Index Per Article: 57.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Collapse
|
26
|
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA. 1. Improving Care and Promoting Health in Populations: Standards of Care in Diabetes-2023. Diabetes Care 2023; 46:S10-S18. [PMID: 36507639 PMCID: PMC9810463 DOI: 10.2337/dc23-s001] [Citation(s) in RCA: 33] [Impact Index Per Article: 33.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Collapse
|
27
|
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA, on behalf of the American Diabetes Association. 16. Diabetes Care in the Hospital: Standards of Care in Diabetes-2023. Diabetes Care 2023; 46:S267-S278. [PMID: 36507644 PMCID: PMC9810470 DOI: 10.2337/dc23-s016] [Citation(s) in RCA: 45] [Impact Index Per Article: 45.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Collapse
|
28
|
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Jeffrie Seley J, Stanton RC, Gabbay RA, on behalf of the American Diabetes Association. 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes-2023. Diabetes Care 2023; 46:S254-S266. [PMID: 36507645 PMCID: PMC9810465 DOI: 10.2337/dc23-s015] [Citation(s) in RCA: 77] [Impact Index Per Article: 77.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Collapse
|
29
|
Leon J, Mata-Ruiz S, Sha P. How Does Nutritional Knowledge of Postpartum Women Participants of the Special Supplemental Nutrition Program for Women Infants and Children (WIC) Program Relate to BMI? J Acad Nutr Diet 2022. [DOI: 10.1016/j.jand.2022.08.103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
30
|
Lamping O, Leon J, Raheel M, Matre N, Lilly S, Harfi T. 485 Right Ventricular Function By Cardiac Computed Tomography As A Predictor Of 1-&3-year Survival Post-TAVI. J Cardiovasc Comput Tomogr 2022. [DOI: 10.1016/j.jcct.2022.06.096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
31
|
Miranda Ruiz E, Gonzalez A, Samos P, Bellsola M, Sabate A, Leon J, Jerónimo M, Pérez-Solà V, Martin L, Corcoles D. Use of verbal de-escalation in reducing need for mechanical restraint in patients with psychotic disorders during non-voluntary transfers from home to the psychiatric emergency department. Eur Psychiatry 2022. [PMCID: PMC9567735 DOI: 10.1192/j.eurpsy.2022.1509] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Introduction Little is known about the need for mechanical restraint during non-voluntary transfers from patient’s homes to the psychiatric emergency department in patients diagnosed with Paranoid Schizophrenia. Although there is no evidence of its efficacy, one of the main tools used for the reduction of mechanical restraints is verbal de-escalation training. Objectives The aim is to describe which symptoms predispose to mechanical restrain in patients with Paranoid Schizophrenia transferred in a non-voluntary manner from home to the psychiatric emergency department, and the effect on reducing mechanical restraints after receiving verbal de-escalation training. Methods All patients with Paranoid Schizophrenia who, after being visited by a home psychiatry team, have required non-voluntary transfer from their homes to the psychiatric emergency department were selected (N = 442). Results Young age, being male, having a poor adherence to treatment, higher scores for de following variables; Excitement, Grandiosity, Suspiciousness, Hostility, Abstract thinking, Motor tension, Uncooperativeness, Poor attention, Lack of insight and Poor impulse control as well as lower scores in motor retardation on the PANSS, are related to a higher frequency of mechanical restrain (P<0,005). Before the verbal de-escalation training, 43.9% of the transferred patients required mechanical restraint, after the training, the need for restraints was reduced to 25.5% (P<0.001). Conclusions Training in verbal de-escalation has allowed an important reduction in mechanical restraints in patients with schizophrenia who have required non-voluntary transfers from home to the psychiatric emergency department. Disclosure No significant relationships.
Collapse
|
32
|
Diskin CJ, Maldonado R, Leon J, Dansby LM, Carter TB, Radcliff L, Diskin CD. How effective is rescue therapeutic plasma exchange in treatment of SARS-Coronavirus-2? Ther Apher Dial 2022; 27:170-176. [PMID: 35490343 PMCID: PMC9348252 DOI: 10.1111/1744-9987.13862] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2021] [Revised: 12/13/2021] [Accepted: 04/26/2022] [Indexed: 01/05/2023]
Abstract
INTRODUCTION After the FDA gave emergency approval for the use of therapeutic plasma exchange in treatment for SARS-Coronoavirus-2, we analyzed its efficacy in patients who had failed all other known therapies. METHODS This was a prospective observational study of 42 patients with SARS-Coronoavirus-2 who had failed conventional therapy and were treated with therapeutic plasma exchange. Pre- and postexchange clinical and laboratory parameters were monitored. The patients were then also compared with a group of 147 patients with SARS-Coronoavirus-2 who were referred for stage 3 acute renal failure and dialysis from SARS-Coronoavirus-2. RESULTS After therapeutic plasma exchange, there were significant improvements in some clinical parameters but mortality remained high; although better than the renal failure group (43.9% vs. 50.7%, p = 0.004). CONCLUSION SARS-CoV-2 patients who failed all other therapies had significant mortality with therapeutic plasma exchange; however, their survival was better than SARS-CoV-2 patients with stage 3 acute renal failure.
Collapse
Affiliation(s)
- Charles J. Diskin
- Hypertension, Nephrology, Dialysis & TransplantationOpelikaAlabamaUSA
| | - Ricardo Maldonado
- Department of Infectious DiseaseEast Alabama Medical CenterOpelikaAlabamaUSA
| | - Jose Leon
- East Alabama Rheumatology CenterOpelikaAlabamaUSA
| | - Linda M. Dansby
- Hypertension, Nephrology, Dialysis & TransplantationOpelikaAlabamaUSA
| | - Thomas B. Carter
- Hypertension, Nephrology, Dialysis & TransplantationOpelikaAlabamaUSA
| | - Lautrec Radcliff
- Hypertension, Nephrology, Dialysis & TransplantationOpelikaAlabamaUSA
| | - Charles D. Diskin
- Hypertension, Nephrology, Dialysis & TransplantationOpelikaAlabamaUSA
| |
Collapse
|
33
|
Patel L, Bridgham K, Ciriello J, Almardawi R, Leon J, Hostetter J, Yazbek S, Raghavan P. PET/MR Imaging in Evaluating Treatment Failure of Head and Neck Malignancies: A Neck Imaging Reporting and Data System-Based Study. AJNR Am J Neuroradiol 2022; 43:435-441. [PMID: 35177543 PMCID: PMC8910793 DOI: 10.3174/ajnr.a7427] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2021] [Accepted: 12/19/2021] [Indexed: 11/07/2022]
Abstract
BACKGROUND AND PURPOSE PET/MR imaging is a relatively new hybrid technology that holds great promise for the evaluation of head and neck cancer. The aim of this study was to assess the performance of simultaneous PET/MR imaging versus MR imaging in the evaluation of posttreatment head and neck malignancies, as determined by its ability to predict locoregional recurrence or progression after imaging. MATERIALS AND METHODS The electronic medical records of patients who had posttreatment PET/MR imaging studies were reviewed, and after applying the exclusion criteria, we retrospectively included 46 studies. PET/MR imaging studies were independently reviewed by 2 neuroradiologists, who recorded scores based on the Neck Imaging Reporting and Data System (using CT/PET-CT criteria) for the diagnostic MR imaging sequences alone and the combined PET/MR imaging. Treatment failure was determined with either biopsy pathology or initiation of new treatment. Statistical analyses including univariate association, interobserver agreement, and receiver operating characteristic analysis were performed. RESULTS There was substantial interreader agreement among PET/MR imaging scores (κ = 0.634; 95% CI, 0.605-0.663). PET/MR imaging scores showed a strong association with treatment failure by univariate association analysis, with P < .001 for the primary site, neck lymph nodes, and combined sites. Receiver operating characteristic curves of PET/MR imaging scores versus treatment failure indicated statistically significant diagnostic accuracy (area under curve range, 0.864-0.987; P < .001). CONCLUSIONS Simultaneous PET/MR imaging has excellent discriminatory performance for treatment outcomes of head and neck malignancy when the Neck Imaging Reporting and Data System is applied. PET/MR imaging could play an important role in surveillance imaging for head and neck cancer.
Collapse
Affiliation(s)
- L.D. Patel
- From the Department of Diagnostic Radiology and Nuclear Medicine, University of Maryland School of Medicine Ringgold Standard Institution, Baltimore, Maryland
| | - K. Bridgham
- From the Department of Diagnostic Radiology and Nuclear Medicine, University of Maryland School of Medicine Ringgold Standard Institution, Baltimore, Maryland
| | - J. Ciriello
- From the Department of Diagnostic Radiology and Nuclear Medicine, University of Maryland School of Medicine Ringgold Standard Institution, Baltimore, Maryland
| | - R. Almardawi
- From the Department of Diagnostic Radiology and Nuclear Medicine, University of Maryland School of Medicine Ringgold Standard Institution, Baltimore, Maryland
| | - J. Leon
- From the Department of Diagnostic Radiology and Nuclear Medicine, University of Maryland School of Medicine Ringgold Standard Institution, Baltimore, Maryland
| | - J. Hostetter
- From the Department of Diagnostic Radiology and Nuclear Medicine, University of Maryland School of Medicine Ringgold Standard Institution, Baltimore, Maryland
| | - S. Yazbek
- From the Department of Diagnostic Radiology and Nuclear Medicine, University of Maryland School of Medicine Ringgold Standard Institution, Baltimore, Maryland
| | - P. Raghavan
- From the Department of Diagnostic Radiology and Nuclear Medicine, University of Maryland School of Medicine Ringgold Standard Institution, Baltimore, Maryland
| |
Collapse
|
34
|
Zhao H, Chan VWS, Castellani D, Chan EOT, Ong WLK, Peng Q, Moschini M, Krajewski W, Pradere B, Ng CF, Enikeev D, Vasdev N, Ekin G, Sousa A, Leon J, Guerrero-Ramos F, Tan WS, Kelly J, Shariat SF, Witjes JA, Teoh JYC. 1459 Intravesical Chemohyperthermia Versus Bacillus Calmette-Guerin Instillation for Intermediate- And High-Risk Non-Muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. Br J Surg 2021. [DOI: 10.1093/bjs/znab259.955] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Abstract
Introduction
Traditional intravesical chemotherapy instillations under room temperature post trans-urethral resection (TUR) of non-muscle invasive bladder cancer (NMIBC) have lower efficacies than maintenance BCG installations. Intravesical chemo-hyperthermia (CHT) at higher temperatures is developed to improve the efficacy of chemotherapy instillation. This systematic review aims to compare the use of CHT and BCG instillation post-TUR.
Method
The protocol of this review is registered on PROSPERO(CRD42020223277). A comprehensive literature search was performed on Medline, EMBASE, and Cochrane CENTRAL to identify studies comparing CHT and BCG post-TUR for intermediate- or high-risk NMIBC. Primary outcomes include recurrence-free survival (RFS) and progression-free survival (PFS). Secondary outcomes include adverse events (AE).
Results
From 2,375 identified records, four randomised control trials incorporating 327 patients were included for meta-analysis. The use of CHT was found to be non-inferior to BCG in RFS, PFS and AEs (Grades 1-3) (p > 0.05). Sensitivity analysis, excluding patients with BCG failures, show 24-36 months recurrence rate to be significantly lower in CHT group (RR 0.64, 95% CI 0.42-0.98, p = 0.04) compared to the BCG group. In patients without carcinoma in situ (CIS), RFS is also significantly better in CHT patients (HR 0.52, 95% CI 0.32- 0.85, p < 0.01). Safety profile remains non-inferior to the BCG group in sensitivity analyses. Quality of evidence across all outcomes ranged from moderate to low.
Conclusions
In well-selected patients, intravesical CHT has superior oncological outcomes and non-inferior safety profile when compared to BCG maintenance therapy for patients with intermediate- and high-risk NMIBC. CHT is a possible alternative treatment during BCG shortage.
Collapse
Affiliation(s)
- H Zhao
- The Chinese University of Hong Kong, Hong Kong, Hong Kong
| | - V W S Chan
- University of Leeds, Leeds, United Kingdom
| | | | - E O T Chan
- The Chinese University of Hong Kong, Hong Kong, Hong Kong
| | - W L K Ong
- Penang General Hospital, Penang, Malaysia
| | - Q Peng
- The Chinese University of Hong Kong, Hong Kong, Hong Kong
| | - M Moschini
- Luzerner Kantonsspital, Lucerne, Switzerland
| | | | - B Pradere
- University Hospital of Tours, Tours, France
| | - C F Ng
- The Chinese University of Hong Kong, Hong Kong, Hong Kong
| | - D Enikeev
- Sechenov University, Moscow, Russian Federation
| | - N Vasdev
- University of Hertfordshire, Hatfield, United Kingdom
| | - G Ekin
- Urla State Hospital, İzmir, Turkey
| | - A Sousa
- Comarcal Hospital, Monforte, Spain
| | - J Leon
- Comarcal Hospital, Monforte, Spain
| | | | - W S Tan
- University College London, London, United Kingdom
- Royal Free Hospital, London, United Kingdom
| | - J Kelly
- University College London, London, United Kingdom
- Royal Free Hospital, London, United Kingdom
| | - S F Shariat
- Medical University of Vienna, Vienna, Austria
- Weill Cornell Medical College, New York, USA
- University of Texas Southwestern, Dallas, USA
- Charles University, Prague, Czech Republic
- The University of Jordan, Amman, Jordan
| | - J A Witjes
- Radboud University Medical Centre, Nijimegen, Netherlands
| | - J Y C Teoh
- The Chinese University of Hong Kong, Hong Kong, Hong Kong
| |
Collapse
|
35
|
Lamping O, Leon J, Lilly S, Matre N, Harfi T. Feasibility And Accuracy Of Quantitative Assessment Of Right Ventricular Size And Function Using Pre Tavi Computed Tomography Scan Compared To Transthoracic Echocardiography. J Cardiovasc Comput Tomogr 2021. [DOI: 10.1016/j.jcct.2021.06.214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
36
|
Bergman L, Acurio J, Leon J, Gatu E, Friis T, Nelander M, Wikström J, Larsson A, Lara E, Aguayo C, Torres-Vergara P, Wikström AK, Escudero C. Preeclampsia and Increased Permeability Over the Blood-Brain Barrier: A Role of Vascular Endothelial Growth Receptor 2. Am J Hypertens 2021; 34:73-81. [PMID: 32866228 DOI: 10.1093/ajh/hpaa142] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2020] [Revised: 06/25/2020] [Accepted: 08/27/2020] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND Cerebral complications in preeclampsia are leading causes of maternal mortality worldwide but pathophysiology is largely unknown and a challenge to study. Using an in vitro model of the human blood-brain barrier (BBB), we explored the role of vascular endothelial growth factor receptor 2 (VEGFR2) in preeclampsia. METHODS The human brain endothelial cell line (hCMEC/D3) cultured on Tranwells insert was exposed (12 hours) to plasma from women with preeclampsia (n = 28), normal pregnancy (n = 28), and nonpregnant (n = 16) controls. Transendothelial electrical resistance (TEER) and permeability to 70 kDa fluorescein isothiocyanate (FITC)-dextran were measured for the assessment of BBB integrity. We explored possible underlying mechanisms, with a focus on the expression of tight junction proteins and phosphorylation of 2 tyrosine residues of VEGFR2, associated with vascular permeability and migration (pY951) and cell proliferation (pY1175). Plasma concentrations of soluble FMS-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) were also measured. RESULTS hCMEC/D3 exposed to plasma from women with preeclampsia exhibited reduced TEER and increased permeability to 70 kDa FITC-dextran. These cells upregulated the messenger ribonucleic acid (mRNA) levels of VEGFR2, and pY951-VEGFR2, but reduced pY1175-VEGFR2 (P < 0.05 in all cases). No difference in mRNA expression of tight junction protein was observed between groups. There was no correlation between angiogenic biomarkers and BBB permeability. CONCLUSIONS We present a promising in vitro model of the BBB in preeclampsia. Selective tyrosine phosphorylation of VEGFR2 may participate in the increased BBB permeability in preeclampsia irrespective of plasma concentrations of angiogenic biomarkers.
Collapse
Affiliation(s)
- Lina Bergman
- Department of Women’s and Children’s Health, Uppsala University, Uppsala,Sweden
- Department of Clinical Sciences, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden
- Department of Obstetrics and Gynecology, Stellenbosch University, Stellenbosch, South Africa
- Vascular Physiology Laboratory, Department of Basic Sciences, Faculty of Sciences, University of Bío-Bío, Chillán, Chile
| | - Jesenia Acurio
- Vascular Physiology Laboratory, Department of Basic Sciences, Faculty of Sciences, University of Bío-Bío, Chillán, Chile
- Group of Research and Innovation in Vascular Health (GRIVAS Health), Chillán, Chile
| | - Jose Leon
- Vascular Physiology Laboratory, Department of Basic Sciences, Faculty of Sciences, University of Bío-Bío, Chillán, Chile
- Group of Research and Innovation in Vascular Health (GRIVAS Health), Chillán, Chile
- Escuela de Enfermería, Facultad de Salud, Universidad Santo Tomás, Los Ángeles, Chile
| | - Emily Gatu
- Department of Women’s and Children’s Health, Uppsala University, Uppsala,Sweden
| | - Therese Friis
- Department of Women’s and Children’s Health, Uppsala University, Uppsala,Sweden
| | - Maria Nelander
- Department of Women’s and Children’s Health, Uppsala University, Uppsala,Sweden
| | - Johan Wikström
- Department of Radiology, Uppsala University, Uppsala, Sweden
| | - Anders Larsson
- Department of Medical Sciences, Clinical Chemistry, Uppsala University, Uppsala, Sweden
| | - Evelyn Lara
- Vascular Physiology Laboratory, Department of Basic Sciences, Faculty of Sciences, University of Bío-Bío, Chillán, Chile
- Group of Research and Innovation in Vascular Health (GRIVAS Health), Chillán, Chile
| | - Claudio Aguayo
- Group of Research and Innovation in Vascular Health (GRIVAS Health), Chillán, Chile
- Department of Clinical Biochemistry and Immunology, Faculty of Pharmacy, University of Concepción, Concepción, Chile
| | - Pablo Torres-Vergara
- Group of Research and Innovation in Vascular Health (GRIVAS Health), Chillán, Chile
- Departamento de Farmacia, Facultad de Farmacia, Universidad de Concepción, Concepción, Chile
| | - Anna-Karin Wikström
- Department of Women’s and Children’s Health, Uppsala University, Uppsala,Sweden
| | - Carlos Escudero
- Vascular Physiology Laboratory, Department of Basic Sciences, Faculty of Sciences, University of Bío-Bío, Chillán, Chile
- Group of Research and Innovation in Vascular Health (GRIVAS Health), Chillán, Chile
| |
Collapse
|
37
|
Bergman L, Acurio J, Leon J, Gatu E, Friis T, Nelander M, Wikström J, Torres P, Wikström AK, Escudero C. Plasma from women with preeclampsia impairs the blood brain barrier in an in vitro model. Pregnancy Hypertens 2019. [DOI: 10.1016/j.preghy.2019.08.099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
38
|
Leon J, Zuber J, Amrouche L, Anglicheau D, Divard G, Bertrand D, Olagne J, Delavenne X, Legendre, Sberro-Soussan R. Les nouveaux anticoagulants oraux directs en transplantation rénale : résultats d’une étude pilote. Nephrol Ther 2019. [DOI: 10.1016/j.nephro.2019.07.056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
39
|
Boudhabhay I, Poillerat V, Torset C, Leon J, Rabant M, Gnemmi V, Frémeaux-Bacchi V, Frimat M, Roumenina L. Insuffisance rénale aiguë et rhabdomyolyse : un rôle clef du complément. Nephrol Ther 2019. [DOI: 10.1016/j.nephro.2019.07.050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
40
|
Bergman L, Torres-Vergara P, Penny J, Wikström J, Nelander M, Leon J, Tolcher M, Roberts JM, Wikström AK, Escudero C. Investigating Maternal Brain Alterations in Preeclampsia: the Need for a Multidisciplinary Effort. Curr Hypertens Rep 2019; 21:72. [PMID: 31375930 DOI: 10.1007/s11906-019-0977-0] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
PURPOSE OF REVIEW To provide insight into the mechanisms underlying cerebral pathophysiology and to highlight possible methods for evaluation, screening, and surveillance of cerebral complications in preeclampsia. RECENT FINDINGS The pathophysiology of eclampsia remains enigmatic. Animal studies show that the cerebral circulation in pregnancy and preeclampsia might be affected with increased permeability over the blood-brain barrier and altered cerebral blood flow due to impaired cerebral autoregulation. The increased blood pressure cannot be the only underlying cause of eclampsia and cerebral edema, since some cases of eclampsia arise without simultaneous hypertension. Findings from animal studies need to be confirmed in human tissues. Evaluation of brain alterations in preeclampsia and eclampsia is challenging and demands a multidisciplinary collaboration, since no single method can accurately and fully describe how preeclampsia affects the brain. Cerebral complications of preeclampsia are significant factors in maternal morbidity and mortality worldwide. No single method can accurately describe the full picture of how preeclampsia affects the brain vasculature and parenchyma. We recommend an international and multidisciplinary effort not only to overcome the issue of limited sample availability but also to optimize the quality of research.
Collapse
Affiliation(s)
- Lina Bergman
- Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
- Center for Clinical Research Dalarna, Falun, Uppsala, Sweden.
| | - Pablo Torres-Vergara
- Pharmacy Department, Faculty of Pharmacy, Universidad de Concepción, Concepción, Chile
- Group of Research and Innovation in Vascular Health (GRIVAS Health), Chillán, Chile
| | - Jeffrey Penny
- Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
| | - Johan Wikström
- Department of Radiology, Uppsala University, Uppsala, Sweden
| | - Maria Nelander
- Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden
| | - Jose Leon
- Group of Research and Innovation in Vascular Health (GRIVAS Health), Chillán, Chile
- Vascular Physiology Laboratory, Group of Investigation in Tumor Angiogenesis, (LFV-GIANT), Department of Basic Sciences, Faculty of Sciences, Universidad del Bío-Bío, Chillán, Chile
| | - Mary Tolcher
- Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden
| | - James M Roberts
- Magee Womens Research Institute, Dept of Obstetrics Gynecology and Reproductive Sciences, Epidemiology and Clinical and Translational Research, University of Pittsburgh, Pittsburgh, PA, USA
| | - Anna-Karin Wikström
- Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden
| | - Carlos Escudero
- Group of Research and Innovation in Vascular Health (GRIVAS Health), Chillán, Chile.
- Vascular Physiology Laboratory, Group of Investigation in Tumor Angiogenesis, (LFV-GIANT), Department of Basic Sciences, Faculty of Sciences, Universidad del Bío-Bío, Chillán, Chile.
| |
Collapse
|
41
|
Lafita-Navarro M, Liano-Pons J, Varela I, Blanco R, Aresti J, Carroll P, Hurlin P, Eisenman R, Delgado M, Leon J. PO-346 The MYC antagonist MNT beyond MAX interaction. ESMO Open 2018. [DOI: 10.1136/esmoopen-2018-eacr25.376] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
42
|
Aalseth CE, Abgrall N, Aguayo E, Alvis SI, Amman M, Arnquist IJ, Avignone FT, Back HO, Barabash AS, Barbeau PS, Barton CJ, Barton PJ, Bertrand FE, Bode T, Bos B, Boswell M, Bradley AW, Brodzinski RL, Brudanin V, Busch M, Buuck M, Caldwell AS, Caldwell TS, Chan YD, Christofferson CD, Chu PH, Collar JI, Combs DC, Cooper RJ, Cuesta C, Detwiler JA, Doe PJ, Dunmore JA, Efremenko Y, Ejiri H, Elliott SR, Fast JE, Finnerty P, Fraenkle FM, Fu Z, Fujikawa BK, Fuller E, Galindo-Uribarri A, Gehman VM, Gilliss T, Giovanetti GK, Goett J, Green MP, Gruszko J, Guinn IS, Guiseppe VE, Hallin AL, Haufe CR, Hehn L, Henning R, Hoppe EW, Hossbach TW, Howe MA, Jasinski BR, Johnson RA, Keeter KJ, Kephart JD, Kidd MF, Knecht A, Konovalov SI, Kouzes RT, LaFerriere BD, Leon J, Lesko KT, Leviner LE, Loach JC, Lopez AM, Luke PN, MacMullin J, MacMullin S, Marino MG, Martin RD, Massarczyk R, McDonald AB, Mei DM, Meijer SJ, Merriman JH, Mertens S, Miley HS, Miller ML, Myslik J, Orrell JL, O'Shaughnessy C, Othman G, Overman NR, Perumpilly G, Pettus W, Phillips DG, Poon AWP, Pushkin K, Radford DC, Rager J, Reeves JH, Reine AL, Rielage K, Robertson RGH, Ronquest MC, Ruof NW, Schubert AG, Shanks B, Shirchenko M, Snavely KJ, Snyder N, Steele D, Suriano AM, Tedeschi D, Tornow W, Trimble JE, Varner RL, Vasilyev S, Vetter K, Vorren K, White BR, Wilkerson JF, Wiseman C, Xu W, Yakushev E, Yaver H, Young AR, Yu CH, Yumatov V, Zhitnikov I, Zhu BX, Zimmermann S. Search for Neutrinoless Double-β Decay in ^{76}Ge with the Majorana Demonstrator. Phys Rev Lett 2018; 120:132502. [PMID: 29694188 DOI: 10.1103/physrevlett.120.132502] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/08/2017] [Revised: 01/09/2018] [Indexed: 06/08/2023]
Abstract
The Majorana Collaboration is operating an array of high purity Ge detectors to search for neutrinoless double-β decay in ^{76}Ge. The Majorana Demonstrator comprises 44.1 kg of Ge detectors (29.7 kg enriched in ^{76}Ge) split between two modules contained in a low background shield at the Sanford Underground Research Facility in Lead, South Dakota. Here we present results from data taken during construction, commissioning, and the start of full operations. We achieve unprecedented energy resolution of 2.5 keV FWHM at Q_{ββ} and a very low background with no observed candidate events in 9.95 kg yr of enriched Ge exposure, resulting in a lower limit on the half-life of 1.9×10^{25} yr (90% C.L.). This result constrains the effective Majorana neutrino mass to below 240-520 meV, depending on the matrix elements used. In our experimental configuration with the lowest background, the background is 4.0_{-2.5}^{+3.1} counts/(FWHM t yr).
Collapse
Affiliation(s)
- C E Aalseth
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - N Abgrall
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - E Aguayo
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - S I Alvis
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - M Amman
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - I J Arnquist
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - F T Avignone
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37830, USA
| | - H O Back
- Department of Physics, North Carolina State University, Raleigh, North Carolina 27695, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
| | - A S Barabash
- National Research Center "Kurchatov Institute" Institute for Theoretical and Experimental Physics, Moscow, 117218 Russia
| | - P S Barbeau
- Department of Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - C J Barton
- Department of Physics, University of South Dakota, Vermillion, South Dakota 57069, USA
| | - P J Barton
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - F E Bertrand
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37830, USA
| | - T Bode
- Max-Planck-Institut für Physik, München, 80805 Germany
| | - B Bos
- South Dakota School of Mines and Technology, Rapid City, South Dakota 57701, USA
| | - M Boswell
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - A W Bradley
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - R L Brodzinski
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - V Brudanin
- Joint Institute for Nuclear Research, Dubna, 141980 Russia
| | - M Busch
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
| | - M Buuck
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - A S Caldwell
- South Dakota School of Mines and Technology, Rapid City, South Dakota 57701, USA
| | - T S Caldwell
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - Y-D Chan
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - C D Christofferson
- South Dakota School of Mines and Technology, Rapid City, South Dakota 57701, USA
| | - P-H Chu
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - J I Collar
- Department of Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - D C Combs
- Department of Physics, North Carolina State University, Raleigh, North Carolina 27695, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
| | - R J Cooper
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37830, USA
| | - C Cuesta
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - J A Detwiler
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - P J Doe
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - J A Dunmore
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - Yu Efremenko
- Department of Physics and Astronomy, University of Tennessee, Knoxville, Tennessee 37916, USA
| | - H Ejiri
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - S R Elliott
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - J E Fast
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - P Finnerty
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - F M Fraenkle
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - Z Fu
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - B K Fujikawa
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - E Fuller
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | | | - V M Gehman
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - T Gilliss
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - G K Giovanetti
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
- Department of Physics, Princeton University, Princeton, New Jersey 08544, USA
| | - J Goett
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - M P Green
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37830, USA
- Department of Physics, North Carolina State University, Raleigh, North Carolina 27695, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - J Gruszko
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - I S Guinn
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - V E Guiseppe
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
- Department of Physics, University of South Dakota, Vermillion, South Dakota 57069, USA
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - A L Hallin
- Centre for Particle Physics, University of Alberta, Edmonton, Alberta T6G 2E1, Canada
| | - C R Haufe
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - L Hehn
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - R Henning
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - E W Hoppe
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - T W Hossbach
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - M A Howe
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - B R Jasinski
- Department of Physics, University of South Dakota, Vermillion, South Dakota 57069, USA
| | - R A Johnson
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - K J Keeter
- Department of Physics, Black Hills State University, Spearfish, South Dakota 57799, USA
| | - J D Kephart
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - M F Kidd
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
- Tennessee Tech University, Cookeville, Tennessee 38505, USA
| | - A Knecht
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - S I Konovalov
- National Research Center "Kurchatov Institute" Institute for Theoretical and Experimental Physics, Moscow, 117218 Russia
| | - R T Kouzes
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - B D LaFerriere
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - J Leon
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - K T Lesko
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - L E Leviner
- Department of Physics, North Carolina State University, Raleigh, North Carolina 27695, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
| | - J C Loach
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
- Shanghai Jiao Tong University, Shanghai 200240, China
| | - A M Lopez
- Department of Physics and Astronomy, University of Tennessee, Knoxville, Tennessee 37916, USA
| | - P N Luke
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - J MacMullin
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - S MacMullin
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - M G Marino
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - R D Martin
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
- Department of Physics, Engineering Physics and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - R Massarczyk
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - A B McDonald
- Department of Physics, Engineering Physics and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - D-M Mei
- Department of Physics, University of South Dakota, Vermillion, South Dakota 57069, USA
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - S J Meijer
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - J H Merriman
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - S Mertens
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
- Max-Planck-Institut für Physik, München, 80805 Germany
- Physik Department and Excellence Cluster Universe, Technische Universität, München, 85748 Germany
| | - H S Miley
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - M L Miller
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - J Myslik
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - J L Orrell
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - C O'Shaughnessy
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - G Othman
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - N R Overman
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - G Perumpilly
- Department of Physics, University of South Dakota, Vermillion, South Dakota 57069, USA
| | - W Pettus
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - D G Phillips
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - A W P Poon
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - K Pushkin
- Department of Physics, University of South Dakota, Vermillion, South Dakota 57069, USA
| | - D C Radford
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37830, USA
| | - J Rager
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - J H Reeves
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - A L Reine
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - K Rielage
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - R G H Robertson
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - M C Ronquest
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - N W Ruof
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - A G Schubert
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - B Shanks
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37830, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - M Shirchenko
- Joint Institute for Nuclear Research, Dubna, 141980 Russia
| | - K J Snavely
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - N Snyder
- Department of Physics, University of South Dakota, Vermillion, South Dakota 57069, USA
| | - D Steele
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - A M Suriano
- South Dakota School of Mines and Technology, Rapid City, South Dakota 57701, USA
| | - D Tedeschi
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - W Tornow
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
| | - J E Trimble
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - R L Varner
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37830, USA
| | - S Vasilyev
- Joint Institute for Nuclear Research, Dubna, 141980 Russia
- Department of Physics and Astronomy, University of Tennessee, Knoxville, Tennessee 37916, USA
| | - K Vetter
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
- Department of Nuclear Engineering, University of California, Berkeley, California 94720, USA
| | - K Vorren
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - B R White
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37830, USA
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - J F Wilkerson
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37830, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - C Wiseman
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - W Xu
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics, University of South Dakota, Vermillion, South Dakota 57069, USA
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - E Yakushev
- Joint Institute for Nuclear Research, Dubna, 141980 Russia
| | - H Yaver
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - A R Young
- Department of Physics, North Carolina State University, Raleigh, North Carolina 27695, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
| | - C-H Yu
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37830, USA
| | - V Yumatov
- National Research Center "Kurchatov Institute" Institute for Theoretical and Experimental Physics, Moscow, 117218 Russia
| | - I Zhitnikov
- Joint Institute for Nuclear Research, Dubna, 141980 Russia
| | - B X Zhu
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - S Zimmermann
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| |
Collapse
|
43
|
Affiliation(s)
- G. Hetsroni
- Department of Nuclear Science and Department of Chemical Engineering TECHNION—Israel Institute of Technology, Haifa, Israel
| | - J. Leon
- Department of Nuclear Science and Department of Chemical Engineering TECHNION—Israel Institute of Technology, Haifa, Israel
| | - M. Hakim
- Department of Nuclear Science and Department of Chemical Engineering TECHNION—Israel Institute of Technology, Haifa, Israel
| |
Collapse
|
44
|
Sánchez EP, Miranda JG, Romero VC, Moreno J, Palma A, Pale LA, Leon J, Bulbena A, Perez V. Describing the assistance, the basis for improvement. Eur Psychiatry 2017. [DOI: 10.1016/j.eurpsy.2017.01.641] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
Abstract
IntroductionConsultation-liaison (CL) psychiatry is a branch of psychiatry that study and treat mental health of patients with other medical or surgical conditions. The assistance between hospitals and health services is heterogeneous.Aims and objectivesFor this reason, the objective of our research is to define the clinical characteristics from our CL service and check out the quality relationship with the applicant service, for improving future assistance.MethodsWe made a descriptive analysis of clinical variables from the patients who received assistance during 2 months by the CL service from the hospital del Mar, Barcelona. We got the frequencies and we used the Chi2 test for the comparison between variables: Diagnosis, appearance in the report and treatment in the report.ResultsTotal of the sample: 42 patients, 61.9% women. Mean age: 55.1 years. Psychiatric diagnosis was present before the assistance on 57.1% of the patients. The most frequent diagnosis was Adjustment Disorder (47.6%) and more than one diagnosis was made in the 14.3%. Near the half of the patients required only primary care assistance after the discharge from the hospital. In the 68.3% of the reports appeared information about CL assistance and the indicated treatment didn’t appear in all the reports. Statistically significant differences weren’t found in the comparisons.ConclusionsAdjustment Disorder is supposed to be the most common psychiatric diagnosis in our CL psychiatry service, as we found in the reviewed literature. The results reveal that relationships between services can be improved. More studies must be done for completing information in this issue.Disclosure of interestThe authors have not supplied their declaration of competing interest.
Collapse
|
45
|
Talamillo A, Grande L, Ruiz-Ontañon P, Velasquez C, Mollinedo P, Torices S, Sanchez-Gomez P, Aznar A, Esparis-Ogando A, Lopez-Lopez C, Lafita C, Berciano MT, Montero JA, Vazquez-Barquero A, Segura V, Villagra NT, Pandiella A, Lafarga M, Leon J, Martinez-Climent JA, Sanz-Moreno V, Fernandez-Luna JL. ODZ1 allows glioblastoma to sustain invasiveness through a Myc-dependent transcriptional upregulation of RhoA. Oncogene 2017; 36:1733-1744. [PMID: 27641332 DOI: 10.1038/onc.2016.341] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2015] [Revised: 08/01/2016] [Accepted: 08/10/2016] [Indexed: 02/06/2023]
Abstract
Long-term survival remains low for most patients with glioblastoma (GBM), which reveals the need for markers of disease outcome and novel therapeutic targets. We describe that ODZ1 (also known as TENM1), a type II transmembrane protein involved in fetal brain development, plays a crucial role in the invasion of GBM cells. Differentiation of glioblastoma stem-like cells drives the nuclear translocation of an intracellular fragment of ODZ1 through proteolytic cleavage by signal peptide peptidase-like 2a. The intracellular fragment of ODZ1 promotes cytoskeletal remodelling of GBM cells and invasion of the surrounding environment both in vitro and in vivo. Absence of ODZ1 by gene deletion or downregulation of ODZ1 by small interfering RNAs drastically reduces the invasive capacity of GBM cells. This activity is mediated by an ODZ1-triggered transcriptional pathway, through the E-box binding Myc protein, that promotes the expression and activation of Ras homolog family member A (RhoA) and subsequent activation of Rho-associated, coiled-coil containing protein kinase (ROCK). Overexpression of ODZ1 in GBM cells reduced survival of xenografted mice. Consistently, analysis of 122 GBM tumour samples revealed that the number of ODZ1-positive cells inversely correlated with overall and progression-free survival. Our findings establish a novel marker of invading GBM cells and consequently a potential marker of disease progression and a therapeutic target in GBM.
Collapse
Affiliation(s)
- A Talamillo
- Unidad de Genética, Hospital Valdecilla-IDIVAL, Santander, Spain
| | - L Grande
- Unidad de Genética, Hospital Valdecilla-IDIVAL, Santander, Spain
| | - P Ruiz-Ontañon
- Unidad de Genética, Hospital Valdecilla-IDIVAL, Santander, Spain
| | - C Velasquez
- Servicio de Neurocirugía, Hospital Valdecilla-IDIVAL, Santander, Spain
| | - P Mollinedo
- Unidad de Genética, Hospital Valdecilla-IDIVAL, Santander, Spain
| | - S Torices
- Unidad de Genética, Hospital Valdecilla-IDIVAL, Santander, Spain
| | - P Sanchez-Gomez
- Unidad de Neuro-Oncología, Instituto de Salud Carlos III (ISCIII), Madrid, Spain
| | - A Aznar
- Centro para la Investigación Médica Aplicada (CIMA), Pamplona, Spain
| | - A Esparis-Ogando
- Centro de Investigación del Cáncer (CSIC-USAL), Salamanca, Spain
| | - C Lopez-Lopez
- Servicio de Oncología Médica, Hospital Valdecilla-IDIVAL, Santander, Spain
| | - C Lafita
- Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), CSIC-Universidad de Cantabria, Santander, Spain
| | - M T Berciano
- Departamento de Anatomía y Biología Celular, Universidad de Cantabria, Santander, Spain
| | - J A Montero
- Departamento de Anatomía y Biología Celular, Universidad de Cantabria, Santander, Spain
| | | | - V Segura
- Centro para la Investigación Médica Aplicada (CIMA), Pamplona, Spain
| | - N T Villagra
- Servicio de Anatomía Patológica, Hospital Valdecilla and Instituto de Investigación Valdecilla (IDIVAL), Santander, Spain
| | - A Pandiella
- Centro de Investigación del Cáncer (CSIC-USAL), Salamanca, Spain
| | - M Lafarga
- Departamento de Anatomía y Biología Celular, Universidad de Cantabria, Santander, Spain
| | - J Leon
- Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), CSIC-Universidad de Cantabria, Santander, Spain
| | | | - V Sanz-Moreno
- Randall Division of Cell and Molecular Biophysics, School of Biomedical and Health Sciences, King's College London, London, UK
| | | |
Collapse
|
46
|
Garcia-Gutierrez L, Bretones G, Arechaga I, Santamaria D, Barbacid M, Leon J. Myc-dependent cell cycle progression through the activation of CDK1 and phosphorylation of p27. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)61270-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
47
|
Lafita M, Liaño J, Ourique F, Aresti J, Hurlin P, Leon J. The expression of MNT, a MYC antagonist, is autoregulated at the mRNA and protein level. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)61064-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
48
|
Leon J, Davila A, Vega R, Chapa C, Islas C, Santos R. Reproductive outcomes in patients with severe OAT/NOA pretreated with FSHr 25 UI and TESE compared with obstructive azoospermia testicular biopsy outcomes: private center experience. Fertil Steril 2015. [DOI: 10.1016/j.fertnstert.2015.07.767] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
49
|
Leon J, Cardenas R, Zapata M, Velasco L. OT-06 * MULTICENTRIC PRIMARY CENTRAL NERVOUS SYSTEM DIFFUSE LARGE B CELL LYMPHOMA IN AN INMUNOCOMPETENT ADOLESCENT, CASE REPORT. Neuro Oncol 2015. [DOI: 10.1093/neuonc/nov061.119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
50
|
Oka S, Leon J, Tsuchimoto D, Sakumi K, Nakabeppu Y. MUTYH, an adenine DNA glycosylase, mediates p53 tumor suppression via PARP-dependent cell death. Oncogenesis 2014; 3:e121. [PMID: 25310643 PMCID: PMC4216901 DOI: 10.1038/oncsis.2014.35] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2014] [Revised: 07/15/2014] [Accepted: 08/25/2014] [Indexed: 12/12/2022] Open
Abstract
p53-regulated caspase-independent cell death has been implicated in suppression of tumorigenesis, however, the regulating mechanisms are poorly understood. We previously reported that 8-oxoguanine (8-oxoG) accumulation in nuclear DNA (nDNA) and mitochondrial DNA triggers two distinct caspase-independent cell death through buildup of single-strand DNA breaks by MutY homolog (MUTYH), an adenine DNA glycosylase. One pathway depends on poly-ADP-ribose polymerase (PARP) and the other depends on calpains. Deficiency of MUTYH causes MUTYH-associated familial adenomatous polyposis. MUTYH thereby suppresses tumorigenesis not only by avoiding mutagenesis, but also by inducing cell death. Here, we identified the functional p53-binding site in the human MUTYH gene and demonstrated that MUTYH is transcriptionally regulated by p53, especially in the p53/DNA mismatch repair enzyme, MLH1-proficient colorectal cancer-derived HCT116+Chr3 cells. MUTYH-small interfering RNA, an inhibitor for p53 or PARP suppressed cell death without an additive effect, thus revealing that MUTYH is a potential mediator of p53 tumor suppression, which is known to be upregulated by MLH1. Moreover, we found that the p53-proficient, mismatch repair protein, MLH1-proficient colorectal cancer cell line express substantial levels of MUTYH in nuclei but not in mitochondria, suggesting that 8-oxoG accumulation in nDNA triggers MLH1/PARP-dependent cell death. These results provide new insights on the molecular mechanism of tumorigenesis and potential new strategies for cancer therapies.
Collapse
Affiliation(s)
- S Oka
- 1] Division of Neurofunctional Genomics, Department of Immunobiology and Neuroscience, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan [2] Research Center for Nucleotide Pool, Kyushu University, Fukuoka, Japan
| | - J Leon
- Division of Neurofunctional Genomics, Department of Immunobiology and Neuroscience, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan
| | - D Tsuchimoto
- 1] Division of Neurofunctional Genomics, Department of Immunobiology and Neuroscience, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan [2] Research Center for Nucleotide Pool, Kyushu University, Fukuoka, Japan
| | - K Sakumi
- 1] Division of Neurofunctional Genomics, Department of Immunobiology and Neuroscience, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan [2] Research Center for Nucleotide Pool, Kyushu University, Fukuoka, Japan
| | - Y Nakabeppu
- 1] Division of Neurofunctional Genomics, Department of Immunobiology and Neuroscience, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan [2] Research Center for Nucleotide Pool, Kyushu University, Fukuoka, Japan
| |
Collapse
|